An Open Label, Randomised, Repeat Dose Study to Assess the Pharmacokinetic Performance of Five Ezogabine/Retigabine Modified Release (MR) Formulations at Steady State Compared to the Immediate Release (IR) Formulation.

This study has been completed.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01332513
First received: April 7, 2011
Last updated: October 20, 2011
Last verified: October 2011

April 7, 2011
October 20, 2011
February 2011
May 2011   (final data collection date for primary outcome measure)
Area under the curve from zero to 24 hours at steady-state of ezogabine [ Time Frame: Days 10, 14, 18, 22, 26 and 30 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01332513 on ClinicalTrials.gov Archive Site
  • Area under the curve of ezogabine from zero to 24 hours at steady-state [ Time Frame: Days 33 and 34 ] [ Designated as safety issue: No ]
  • Cmax of ezogabine at steady state [ Time Frame: Days 10, 14, 18, 22, 26, 30, 33 and 34 ] [ Designated as safety issue: No ]
  • Tmax of ezogabine at steady-state [ Time Frame: Days 10, 14, 18, 22, 26, 30, 33 and 34 ] [ Designated as safety issue: No ]
  • Cmin of ezogabine at steady state [ Time Frame: Days 10, 14, 18, 22, 26, 30, 33 and 34 ] [ Designated as safety issue: No ]
  • Cmax:Cmin Ratio of ezogabine [ Time Frame: Days 10, 14, 18, 22, 26, 30, 33 and 34 ] [ Designated as safety issue: No ]
  • Fluctuation Index (FI) of ezogabine [ Time Frame: Days 10, 14, 18, 22, 26, 30, 33 and 34 ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
An Open Label, Randomised, Repeat Dose Study to Assess the Pharmacokinetic Performance of Five Ezogabine/Retigabine Modified Release (MR) Formulations at Steady State Compared to the Immediate Release (IR) Formulation.
An Open Label, Randomised, Repeat Dose Study to Assess the Pharmacokinetic Performance of Five Ezogabine/Retigabine Modified Release (MR) Formulations at Steady State Compared to the Immediate Release (IR) Formulation.

This is an open-label, single centre, repeat dose, up- titration study in healthy male and female subjects to assess the pharmacokinetic (PK) performance of five prototypes of ezogabine modified release tablet formulations.

The study will consist of a screening period, a treatment phase (consisting of a titration phase, bioavailability phase and food effect phase) and a post-treatment follow-up visit. The study duration from screening to follow up will be approximately 7 weeks. No study procedures will start before informed consent is obtained. Subjects will remain in the clinical unit for the duration of the treatment period (35 days).

Subjects will receive repeat doses of ezogabine for up to 34 days starting at a dose of 100 mg IR TID (300mg TDD) with a standard meal (to be consumed 30 min prior to dosing) for Days 1-3, on days 4-6 subjects will receive 150mg IR TID (450mg TDD). On Day 7 through to the end of the study subjects will receive ezogabine (Mr or IR) at a dose of 600mgTDD.

On Day 7 subjects will enter into a 6-way cross over period to investigate the 5 MR formulations being tested (each at 300mg BID) and the single IR formulation (at 200mg TID). Subjects will receive each formulaition for 4 days and blood samples for pharmacokinetic analysis will be collected up to 24 hours post dose on each 4th day (PK days).

On Day 31 subjects will enter into a food effect phase to investigate the 5 MR formulations being tested (each at 600mg QD). Subjects in this period will have a PK day on Day 33 (following a standard breakfast), and on Day 34 (following a high fat breakfast) to investigate a food effect on the PK profile of ezogabine.

Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Masking: Open Label
Primary Purpose: Treatment
Epilepsy
  • Drug: Investigational Medicinal Product (MR1)
  • Drug: Investigational Medicinal Product (MR2)
  • Drug: Investigational Medicinal Product (MR3)
  • Drug: Investigational Medicinal Product (MR4)
  • Drug: Investigational Medicinal Product (MR5)
  • Drug: Investigational Medicinal Product (IR)
Experimental: Investigational Medicinal Product
Interventions:
  • Drug: Investigational Medicinal Product (MR1)
  • Drug: Investigational Medicinal Product (MR2)
  • Drug: Investigational Medicinal Product (MR3)
  • Drug: Investigational Medicinal Product (MR4)
  • Drug: Investigational Medicinal Product (MR5)
  • Drug: Investigational Medicinal Product (IR)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
36
June 2011
May 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Healthy as determined by a responsible and experienced physician
  2. Male or female between 18 and 60 years of age inclusive, at the time of signing the informed consent.
  3. A female subject is eligible to participate if she is of:

    • Non-childbearing potential defined
    • Child-bearing potential and agrees to use one of the contraception methods listed
  4. Male subjects must agree to use one of the contraception methods listed
  5. Body weight > 50 kg and body mass index (BMI) within the range of 18 - 30kg/m2 (inclusive).
  6. Normal or High Normal blood pressure
  7. 24hr holter with no clinically significant findings.
  8. QTcB or QTcF < 450 msec at screening and pre-dose.
  9. Creatinine Clearance within the normal range at screening and pre-dose.
  10. Liver function test within normal limits at screening and pre-dose.
  11. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

Exclusion Criteria:

A subject will not be eligible for inclusion in this study if any of the following criteria apply:

  1. Subjects who are vegetarian or vegan, or for any other reason be unwilling to consume a high fat meal.
  2. The subject has either a previous disease or current medical condition
  3. Has made a suicide attempt in the past or, in the investigator's judgment, poses significant suicide risk.
  4. Presence of clinically significant proteinuria or hematuria or other clinically significant findings in urinalysis.
  5. Subjects with symptoms of urinary dysfunction.
  6. Subjects whose ECG shows PR interval is >220 msec, or presence of intraventricular conduction disturbances (complete or incomplete BBB), at screening or prior to dosing.
  7. Presence of clinically significant arrhythmias.
  8. A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
  9. Current or chronic liver disease or biliary abnormalities. Medical history positive for biliary signs and symptoms (cholecystectomy is acceptable).
  10. History of regular alcohol consumption within 6 months of the study.
  11. A positive drug/alcohol screen at screening and / or pre-dose.
  12. A positive test for HIV antibody.
  13. The subjects smokes more than 10 cigarettes per week.
  14. The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  15. Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
  16. Use of prescription or non-prescription drugs.
  17. History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy.
  18. Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
  19. Pregnant females as determined by positive serum hCG test at screening or prior to dosing.
  20. Lactating females.
  21. Unwillingness or inability to follow the procedures outlined in the protocol.
  22. Subject is mentally or legally incapacitated.
Both
18 Years to 60 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01332513
114552
No
Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure
GlaxoSmithKline
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
October 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP